How Pharma Price Gouging Has Left Americans in a Helpless State

PUBLISHED BY
Christy Gren



TAGS:


2 years ago




“Americans pay the highest drug prices in the world because pharma companies need the bounty for Research and Development.” We often come across this narrative put across by pharma lobbyists to justify pharma price gouging. American pharma companies spent billions of dollars on R&D and this effort in creating new drugs has certainly helped the world in many ways. But does that justify the high prices Americans are paying for some important, life-saving drugs? The high profits that some pharma companies are earning, how much of it is actually used for research?

Consider the example of Turing pharmaceuticals that acquired the drug Daraprim, a drug used in treating an illness associated with AIDS, when its patent had expired. Generally, once the patent of a new drug expires, generic variants enter and are sold in the market at low prices. Since the R&D costs and production costs of companies producing such generic drugs are low, they are able to sell them to the public at low prices.  Turing seized the day and acquired Daraprim at a time when there were no generic variants available. But, instead of lowering the cost or even keeping it unchanged, Turing hiked the price by more than forty-folds. The price of Daraprim increased from $13.50 to $750, practically overnight.

 

 

“Is this price manipulation even legal?” one might ask. It is!

The US follows a free market system of pricing for pharmaceutical products. Pharma companies are free to price their drugs however they want and that is exactly what they do. Daraprim isn’t the only example. Recently, we have seen several instances of pharma price gouging. After Valeant Pharma acquired Isuprel and Nitropress from Marathon Pharma, Valeant increased their prices by 525 percent and 212 percent respectively.

The public is both at the beginning and the end of the funnel. They pay high prices to buy these drugs and they also pay for creating these drugs. These Pharma companies often acquire drugs created as a result of NIH- funded university research. Furthermore, American pharma companies can take a tax write-off on their direct-to-consumer advertising. So, while the burden of high prices and research funding is carried by the general public, big pharma companies enjoy massive profits. According to a report by Axios, while pharma companies bring in 23 percent of health care’s US revenues, they make 63 percent of the total profits. Since such companies have monopolies over these vital drugs, pharma price gouging leaves the public in an “it’s either pay or suffer” situation.

When contested, these pharma companies often hide behind the same narrative – “profits from high prices are required to fund Research & Development.” But in reality, these pharma companies seldom introduce any ground-breaking drugs instead, they introduce “follow-on” drugs. Follow-on drugs are the drugs which are very similar to the existing drugs but are marketing with new names, labels and with a claim of having a better therapeutic action. While some follow-on drugs are regarded by the FDA as having some improvement, 67 percent are conferred as having no significant benefit. The term “me-too drugs” that is often attributed to such follow-on drugs, thus, seems to be very apt.

Christy Gren
Christy Gren is an Industry Specialist Reporter at Industry Leaders Magazine she enjoys writing about Unicorns, Silicon Valley, Startups, Business Leaders and Innovators. Her articles provide an insight about the Power Players in the field of Technology, Auto, Manufacturing, and F&B.

Recent Posts

Ikea and Rockefeller Foundations to raise $10 billion for renewable energy projects in poor countries

Ikea and Rockefeller Foundations to raise $10 billion for renewable energy projects in poor countries

The Ikea and Rockefeller foundations are jointly launching a $10 billion fund to promote small-scale renewable power projects in developing nations. Both
13 hours ago
EC initiates another probe into Google’s adtech practices

EC initiates another probe into Google’s adtech practices

EU antitrust regulators are planning a formal investigation into Google’s digital advertising practices by the end of this year. Google is already facing unprecedented regulatory
20 hours ago
Some Microsoft employees stayed at data centers during Pandemic to keep all systems going

Some Microsoft employees stayed at data centers during Pandemic to keep all systems going

The Covid-19 pandemic ravaging the world for more than a year has forced companies and organizations to find viable solutions to keep the business going. Most found a solution in w
1 day ago
Meme stocks frenzy and 3 companies to follow

Meme stocks frenzy and 3 companies to follow

The doom and gloom about the stock market that has been predicted since the pandemic started has abated somewhat with the resilience shown by investors (helped by low-interest rate
1 day ago
US Space Force allows repurposed SpaceX rocket to launch GPS satellite

US Space Force allows repurposed SpaceX rocket to launch GPS satellite

A GPS navigation satellite built by Lockheed Martin is set to ride a reused SpaceX booster on a launch from Cape Canaveral, Florida, Thursday. It will be the first time a military
3 days ago
Disney boss says 40 pc ad revenue went to streaming sites, no plans of ad supported Disney+

Disney boss says 40 pc ad revenue went to streaming sites, no plans of ad supported Disney+

Walt Disney CEO Bob Chapel says the company’s advertising revenue for the upcoming fall television season was strong and went up by “double-digits” compared to 2019.
6 days ago